Effects of long-term benzodiazepine use
The core structure of benzodiazepines. "R" labels denote common locations of side chains, which give different benzodiazepines their unique properties.
|Classification and external resources|
The effects of long-term benzodiazepine use include drug dependence as well as the possibility of adverse effects on cognitive function, physical health, and mental health. Benzodiazepines are generally effective when used therapeutically in the short-term. Most of the problems associated with benzodiazepines result from their long-term use. There are significant physical, mental and social risks associated with the long-term use of benzodiazepines. There is evidence that reduction or withdrawal from benzodiazepines can lead to a reduction in anxiety symptoms. Due to these increasing physical and mental symptoms from long-term use of benzodiazepines, slowly withdrawing from benzodiazepines is recommended for many long-term users. Not everyone, however, experiences problems with long-term use.
Some of the symptoms that could possibly occur as a result of a withdrawal from benzodiazepines after long-term use include emotional clouding, flu-like symptoms, nausea, headaches, dizziness, irritability, lethargy, sleep problems, memory impairment, personality changes, aggression, depression, social deterioration as well as employment difficulties, while others never have any side effects from long term benzodiazepine use. One should never abruptly stop using this medicine and should wean themself down to a lower dose under doctor supervision. While benzodiazepines are highly effective in the short term, adverse effects in some people associated with long-term use including impaired cognitive abilities, memory problems, mood swings, overdoses when combined with other drugs may make the risk-benefit ratio unfavourable, while others experience no ill effects. In addition, benzodiazepines have reinforcing properties in some individuals and thus are considered to be addictive drugs especially in individuals that have a "drug-seeking" behavior; in addition, a physical dependence can develop after a few weeks or months of use. Many of these adverse effects of long-term use of benzodiazepines begin to show improvements three to six months after withdrawal.
Other concerns about the effects of long-term benzodiazepine use, in some, include dose escalation, benzodiazepine abuse, tolerance and benzodiazepine dependence and benzodiazepine withdrawal problems. Both physiological tolerance and dependence can lead to a worsening of the adverse effects of benzodiazepines. Increased risk of death has been associated with long-term use of benzodiazepines in several studies, however, other studies have not found increased mortality. Due to conflicting findings in studies regarding benzodiazepines and increased risks of death including from cancer, further research in long-term use of benzodiazepines and mortality risk has been recommended. Most of the research has been conducted in prescribed users of benzodiazepines; even less is known about the mortality risk of illicit benzodiazepine users. The long-term use of benzodiazepines is controversial and has generated significant controversy within the medical profession. Views on the nature and severity of problems with long-term use of benzodiazepines differ from expert to expert and even from country to country; some experts even question whether there is any problem with the long-term use of benzodiazepines. Political controversy, in particular in the UK, also surrounds the long-term use of benzodiazepines, and was subject to the largest class-action lawsuit in the 1980s and 1990s. There have also been allegations of a cover-up by medical bureaucracies and the government.[better source needed]
- 1 Symptoms
- 2 History
- 3 Special populations
- 4 See also
- 5 References
Effects of long-term benzodiazepine use may include disinhibition, impaired concentration and memory, depression, as well as sexual dysfunction. The long-term effects of benzodiazepines may differ from the adverse effects seen after acute administration of benzodiazepines. An analysis of cancer patients found that those who took tranquillisers or sleeping tablets had a substantially poorer quality of life on all measurements conducted, as well as a worse clinical picture of symptomatology. Worsening of symptoms such as fatigue, insomnia, pain, dyspnea and constipation was found when compared against those who did not take tranquillisers or sleeping tablets. Most individuals who successfully discontinue hypnotic therapy after a gradual taper and do not take benzodiazepines for 6 months have less severe sleep and anxiety problems, are less distressed and have a general feeling of improved health at 6 month follow up. The use of benzodiazepines for the treatment of anxiety has been found to lead to a significant increase in healthcare costs due to accidents and other adverse effects associated with the long-term use of benzodiazepines.[medical citation needed]
Long-term benzodiazepine use can lead to a generalised impairment of cognition, including sustained attention, verbal learning and memory and psychomotor, visuo-motor and visuo-conceptual abilities. These effects on cognition exist, although their impact on patient's daily functioning is, in most (but not all cases), insignificant. Transient changes in the brain have been found using neuroimaging studies, but no brain abnormalities have been found in patients treated long term with benzodiazepines. When benzodiazepine users cease long-term benzodiazepine therapy, their cognitive function improves in the first six months, although deficits may be permanent or take longer than six months to return to baseline. In the elderly, long-term benzodiazepine therapy is a risk factor for amplifying cognitive decline, although gradual withdrawal is associated with improved cognitive status. A study of alprazolam found that 8 weeks administration of alprazolam resulted in deficits that were detectable after several weeks but not after 3–5 years.[medical citation needed]
Effect on sleep
Sleep architecture can be adversely affected by benzodiazepine dependence. Possible adverse effects on sleep include induction or worsening of sleep disordered breathing. Like alcohol, benzodiazepines are commonly used to treat insomnia in the short-term (both prescribed and self-medicated), but worsen sleep in the long-term. Although benzodiazepines can put people to sleep, while asleep, the drugs disrupt sleep architecture: decreasing sleep time, delaying time to and decreased REM sleep, increasing alpha and beta activity, decreasing K complexes and delta activity, and decreasing deep slow-wave sleep (i.e., NREM stage 3 and 4, the most restorative part of sleep for both energy and mood).
Mental and physical health
The long-term use of benzodiazepines may have a similar effect on the brain as alcohol, and are also implicated in depression, anxiety, posttraumatic stress disorder (PTSD), mania, psychosis, sleep disorders, sexual dysfunction, delirium, and neurocognitive disorders (including benzodiazepine-induced persisting dementia which persists even after the medications are stopped). As with alcohol, the effects of benzodiazepine on neurochemistry, such as decreased levels of serotonin and norepinephrine, are believed to be responsible for their effects on mood and anxiety. Additionally, benzodiazepines can indirectly cause or worsen other psychiatric symptoms (e.g., mood, anxiety, psychosis, irritability) by worsening sleep (i.e., benzodiazepine-induced sleep disorder).
Long-term benzodiazepine use may lead to the creation or exacerbation of physical and mental health conditions, which improve after 6 or more months of abstinence. After a period of about 3 to 6 months of abstinence after completion of a gradual-reduction regimen, marked improvements in mental and physical wellbeing become apparent. For example, one study of hypnotic users gradually withdrawn from their hypnotic medication reported after 6 months of abstinence that they had less severe sleep and anxiety problems, were less distressed, and had a general feeling of improved health. Those having remained on hypnotic medication had no improvements in their insomnia, anxiety, or general health ratings. A study found that individuals having withdrawn from benzodiazepines showed a marked reduction in use of medical and mental health services.[medical citation needed]
Approximately half of patients attending mental health services for conditions including anxiety disorders such as panic disorder or social phobia may be the result of alcohol or benzodiazepine dependence. Sometimes anxiety disorders pre-existed alcohol or benzodiazepine dependence but the alcohol or benzodiazepine dependence often act to keep the anxiety disorders going and often progressively making them worse.[medical citation needed] Many people who are addicted to alcohol or prescribed benzodiazepines when it is explained to them they have a choice between ongoing ill mental health or quitting and recovering from their symptoms decide on quitting alcohol and or their benzodiazepines. It was noted that every individual has an individual sensitivity level to alcohol or sedative hypnotic drugs and what one person can tolerate without ill health another will suffer very ill health and that even moderate drinking in sensitive individuals can cause rebound anxiety syndromes and sleep disorders. A person who is suffering the toxic effects of alcohol or benzodiazepines will not benefit from other therapies or medications as they do not address the root cause of the symptoms. Recovery from benzodiazepine dependence tends to take a lot longer than recovery from alcohol but people can regain their previous good health. A review of the literature regarding benzodiazepine hypnotic drugs concluded that these drugs cause an unjustifiable risk to the individual and to public health. The risks include dependence, accidents and other adverse effects. Gradual discontinuation of hypnotics leads to improved health without worsening of sleep.
Daily users of benzodiazepines are also at a higher risk of experiencing psychotic symptomatology such as delusions and hallucinations. A study found that of 42 patients treated with alprazolam, up to a third of long-term users of the benzodiazepine drug alprazolam (Xanax) develop depression. Studies have shown that long-term use of benzodiazepines and the benzodiazepine receptor agonist nonbenzodiazepine Z drugs are associated with causing depression as well as a markedly raised suicide risk and an overall increased mortality risk.
A study of 50 patients who attended a benzodiazepine withdrawal clinic found that long-term use of benzodiazepines causes a wide range of psychological and physiological disorders. It was found that, after several years of chronic benzodiazepine use, a large portion of patients developed various mental and physical health problems including agoraphobia, irritable bowel syndrome, paraesthesiae, increasing anxiety, and panic attacks, which were not preexisting. The mental health and physical health symptoms induced by long-term benzodiazepine use gradually improved significantly over a period of a year following completion of a slow withdrawal. Three of the 50 patients had wrongly been given a preliminary diagnosis of multiple sclerosis when the symptoms were actually due to chronic benzodiazepine use. Ten of the patients had taken drug overdoses whilst on benzodiazepines, despite the fact that only two of the patients had any prior history of depressive symptomatology. After withdrawal, no patients took any further overdoses after 1 year post-withdrawal. The cause of the deteriorating mental and physical health in a significant proportion of patients was hypothesised to be caused by increasing tolerance where withdrawal type symptoms emerged, despite the administration of stable prescribed doses. Another theory is that chronic benzodiazepine use causes subtle increasing toxicity, which in turn leads to increasing psychopathology in long-term users of benzodiazepines.
Long-term use of benzodiazepines can induce perceptual disturbances and depersonalisation in some people, even in those taking a stable daily dosage, and it can also become a protracted withdrawal feature of the benzodiazepine withdrawal syndrome.
In addition, chronic use of benzodiazepines is a risk factor for blepharospasm. Drug-induced symptoms that resemble withdrawal-like effects can occur on a set dosage as a result of prolonged use, also documented with barbiturate-like substances, as well as alcohol and benzodiazepines. This demonstrates that the effects from chronic use of benzodiazepine drugs is not unique but occurs with other GABAergic sedative hypnotic drugs, i.e., alcohol and barbiturates.
Chronic use of benzodiazepines seemed to cause significant immunological disorders in a study of selected outpatients attending a psychopharmacology department. Diazepam and clonazepam have been found to have long-lasting, but not permanent, immunotoxic effects in the fetus of pregnant rats. However, single very high doses of diazepam have been found to cause lifelong immunosuppression in neonatal rats. No studies have been done to assess the immunotoxic effects of diazepam in humans; however, high prescribed doses of diazepam, in humans, has been found to be a major risk of pneumonia, based on a study of people with tetanus. It has been proposed that diazepam may cause long-lasting changes to the GABAA receptors with resultant long-lasting disturbances to behaviour, endocrine function and immune function
Suicide and self-harm
Because benzodiazepines in general may be associated with increased suicide risk, care should be taken when prescribing especially to at risk patients. Depressed adolescents who were taking benzodiazepines were found to have a greatly increased risk of self-harm or suicide, although the sample size was small. The effects of benzodiazepines in individuals under the age of 18 requires further research. Additional caution is required in using benzodiazepines in depressed adolescents. Benzodiazepine dependence often results in an increasingly deteriorating clinical picture, which includes social deterioration leading to comorbid alcoholism and drug abuse. Suicide is a common outcome of chronic benzodiazepine dependence. Benzodiazepine misuse or misuse of other CNS depressants increases the risk of suicide in drug misusers. 11% of males and 23% of females with a sedative hypnotic misuse habit commit suicide.
There has been some controversy around the possible link between benzodiazepine use and development of cancer; early cohort studies in the 1980s suggested a possible link, but follow-up case-control studies have found no link between benzodiazepines and cancer. In the second U.S. national cancer study in 1982, the American Cancer Society conducted a survey of over 1.1 million participants. A marked increased risk of cancer was found in the users of sleeping pills, mainly benzodiazepines. There have been 15 epidemiologic studies that have suggested that benzodiazepine or nonbenzodiazepine hypnotic drug use is associated with increased mortality, mainly due to increased cancer deaths in humans. The cancers included cancer of the brain, lung, bowel, breast, and bladder, and other neoplasms. It has been hypothesised that either depressed immune function or the viral infections themselves were the cause of the increased rates of cancer. While initially U.S. Food and Drug Administration reviewers expressed concerns about approving the nonbenzodiazepine Z drugs due to concerns of cancer, ultimately they changed their minds and approved the drugs. A recent case-control study, however, found no link between use of benzodiazepines and cancers of the breast, lung, large bowel, lung, uterine lining, ovaries, testes, thyroid, liver, or Hodgkin's Disease, melanoma, or non-Hodgkin's lymphoma. More specific case-control studies since 2000 have shown no link between benzodiazepine use and breast cancer. One study found an association between self-reported benzodiazepine use and development of ovarian cancer, whereas another study found no relationship.
Brain damage evidence
In a study in 1980 in a group of 55 consecutively admitted patients having abused exclusively sedatives or hypnotics, neuropsychological performance was significantly lower and signs of intellectual impairment significantly more often diagnosed than in a matched control group taken from the general population. These results suggested a relationship between abuse of sedatives or hypnotics and cerebral disorder.
In a study in 1984, 20 patients having taken long-term benzodiazepines were submitted to brain CT scan examinations. Some scans appeared abnormal. The mean ventricular-brain ratio measured by planimetry was increased over mean values in an age- and sex-matched group of control subjects but was less than that in a group of alcoholics. There was no significant relationship between CT scan appearances and the duration of benzodiazepine therapy. The clinical significance of the findings was unclear.
In 1987, 17 high-dose inpatient abusers of benzodiazepines have anecdotally shown enlarged cerebrospinal fluid spaces with associated brain shrinkage. Brain shrinkage reportedly appeared to be dose dependent with low-dose users having less brain shrinkage than higher-dose users.
However, a CT study in 1987 found no evidence of brain shrinkage in prescribed benzodiazepine users.
In 1989, in a 4- to 6-year follow-up study of 30 inpatient benzodiazepine abusers, Neuropsychological function was found to be permanently affected in some chronic high-dose abusers of benzodiazepines . Brain damage similar to alcoholic brain damage was observed. The CT scan abnormalities showed dilatation of the ventricular system. However, unlike alcoholics, sedative hypnotic abusers showed no evidence of widened cortical sulci. The study concluded that, when cerebral disorder is diagnosed in sedative hypnotic benzodiazepine abusers, it is often permanent.
A CT study in 1993 investigated brain damage in benzodiazepine users and found no overall differences to a healthy control group.
A study in 2000 found that long-term benzodiazepine therapy does not result in brain abnormalities.
Withdrawal from high-dose abuse of nitrazepam anecdotally was alleged in 2001 to have caused severe shock of the whole brain with diffuse slow activity on EEG in one patient after 25 years of abuse. After withdrawal, abnormalities in hypofrontal brain wave patterns persisted beyond the withdrawal syndrome, which suggested to the authors that organic brain damage occurred from chronic high-dose abuse of nitrazepam.
Professor Ashton, a leading expert on benzodiazepines from Newcastle University Institute of Neuroscience, has stated that there is no structural damage from benzodiazepines, and advocates for further research into long-lasting or possibly permanent symptoms of long-term use of benzodiazepines as of 1996. She has stated that she believes that the most likely explanation for lasting symptoms is persisting but slowly resolving functional changes at the GABAA benzodiazepine receptor level. Newer and more detailed brain scanning technologies such as PET scans and MRI scans had as of 2002 to her knowledge never been used to investigate the question of whether benzodiazepines cause functional or structural brain damage.
In 2014 studies have found an association between the use of benzodiazepines and an increased risk of dementia but the exact nature of the relationship is still a matter of debate.
Benzodiazepines when introduced in 1961 were widely believed to be safe drugs but as the decades went by increased awareness of adverse effects connected to their long-term use became known. There was initially widespread public approval but this was followed by widespread public disapproval and recommendations for more restrictive medical guidelines followed. Concerns regarding the long-term effects of benzodiazepines have been raised since 1980. These concerns are still not fully answered. A review in 2006 of the literature on use of benzodiazepine and nonbenzodiazepine hypnotics concluded that more research is needed to evaluate the long-term effects of hypnotic drugs. The majority of the problems of benzodiazepines are related to their long-term use rather than their short-term use. There is growing evidence of the harm of long-term use of benzodiazepines, especially at higher doses. In 2007 the Department of Health recommended that individuals on long-term benzodiazepines are monitored at least every 3 months and also recommends against long-term substitution therapy in benzodiazepine drug misusers due to a lack of evidence base for effectiveness and due to the risks of long-term use. The long-term effects of benzodiazepines are very similar to the long-term effects of alcohol (apart from organ toxicity) and other sedative-hypnotics. Withdrawal effects and dependence are almost identical. A report in 1987 by the Royal College of Psychiatrists in Great Britain reported that any benefits of long-term use of benzodiazepines are likely to be far outweighed by the risks of long-term use. Despite this benzodiazepines are still widely prescribed. The socioeconomic costs of the continued widespread prescribing of benzodiazepines is high.
The Medical Research Council in 1980 recommended that research be conducted into the effects of long-term use of benzodiazepines A 2009 British Government parliamentary inquiry recommended that research into the long-term effects of benzodiazepines must be carried out. The view of the Department of Health is that they have made every effort to make doctors aware of the problems associated with the long-term use of benzodiazepines, as well as the dangers of benzodiazepine drug addiction.
In 1980, the Medicines and Healthcare products Regulatory Agency's Committee on the Safety of Medicines issued guidance restricting the use of benzodiazepines to short-term use and updated and strengthened these warnings in 1988. When asked by Phil Woolas in 1999 whether the Department of Health had any plans to conduct research into the long-term effects of benzodiazepines, the Department replied, saying they have no plans to do so, as benzodiazepines are already restricted to short-term use and monitored by regulatory bodies. In a House of Commons debate, Phil Woolas has claimed that there has been a cover-up with regard to the problems associated with benzodiazepines because they are of too large of a scale for governments, regulatory bodies, and the pharmaceutical industry to deal with. John Hutton stated in response that the Department of Health take the problems of benzodiazepines extremely seriously and are not sweeping the issue under the carpet. In 2010, the All-Party Parliamentary Group on Involuntary Tranquilliser Addiction filed a complaint with the Equality and Human Rights Commission under the Disability Discrimination Act 1995 against the Department of Health and the Department for Work and Pensions alleging discrimation against people with a benzodiazepine prescription drug dependence as a result of denial of specialised treatment services, exclusion from medical treatment, non-recognition of the protracted benzodiazepine withdrawal syndrome, as well as denial of rehabilitation and back to work schemes. Additionally the APPGITA complaint alleged that there is a "virtual prohibition" on the collection of statistical information on benzodiazepines across government departments, whereas with other controlled drugs there are enormous volumes of statistical data. The complaint alleged that the discrimination is deliberate, large scale and that government departments are aware of what they are doing.
Declassified Medical Research Council meeting
The Medical Research Council (UK) held a closed meeting among top UK medical doctors and representatives from the pharmaceutical industry between the dates of 30 October 1980 and 3 April 1981. The meeting was classified under the Public Records Act 1958 until 2014 but became available in 2005 as a result of the Freedom of Information Act. The meeting was called due to concerns that 10–100,000 people could be dependent; this estimate was later revised by the Chairman Professor Malcolm Lader, of the meeting to approximately half a million members of the British public were suspected of being dependent on therapeutic dose levels of benzodiazepines, about half of those on long-term benzodiazepines. It was reported that benzodiazepines may be the third- or fourth-largest drug problem in the UK (the largest being alcohol and tobacco). The Chairman of the meeting followed up after the meeting with additional information, which was forwarded to the Medical Research Council neuroscience board, raising concerns regarding tests that showed definite cortical atrophy in 2 of 14 individuals tested and borderline abnormality in five others. He felt that, due to the methodology used in assessing the scans, the abnormalities were likely an underestimate, and more refined techniques would be more accurate. Also discussed were findings that tolerance to benzodiazepines can be demonstrated by injecting diazepam into long-term users; in normal subjects, increases in growth hormone occurs, whereas in benzodiazepine-tolerant individuals this effect is blunted. Also raised were findings in animal studies that showed the development of tolerance in the form of a 15 percent reduction in binding capacity of benzodiazepines after seven days administration of high doses of the partial agonist benzodiazepine drug flurazepam and a 50 percent reduction in binding capacity after 30 days of a low dose of diazepam. The Chairman was concerned that papers soon to be published would "stir the whole matter up" and wanted to be able to say that the Medical Research Council "had matters under consideration if questions were asked in parliament". The Chairman felt that it "was very important, politically that the MRC should be 'one step ahead'" and recommended epidemiological studies be funded and carried out by Roche Pharmaceuticals and MRC sponsored research conducted into the biochemical effects of long-term use of benzodiazepines. The meeting aimed to identify issues that were likely to arise, alert the Department of Health to the scale of the problem and identify the pharmacology and nature of benzodiazepine dependence and the volume of benzodiazepines being prescribed. The World Health Organisation was also interested in the problem and it was felt the meeting would demonstrate to the WHO that the MRC was taking the issue seriously. Among the psychological effects of long-term use of benzodiazepines discussed was a reduced ability to cope with stress. The Chairman stated that the "withdrawal symptoms from valium were much worse than many other drugs including, e.g., heroin". It was stated that the likelihood of withdrawing from benzodiazepines was "reduced enormously" if benzodiazepines were prescribed for longer than four months. It was concluded that benzodiazepines are often prescribed inappropriately, for a wide range of conditions and situations. Dr Mason (DHSS) and Dr Moir (SHHD), felt it important to determine the effectiveness and toxicity of benzodiazepines due to the large numbers of people using benzodiazepines for long periods of time before deciding what regulatory action to take.[not in citation given]
Controversy resulted in 2010 when the previously secret files came to light over the fact that the Medical Research Council was warned that benzodiazepines prescribed to millions of patients appeared to cause brain shrinkage similar to alcohol abuse in some patients and failed to carry out larger and more rigorous studies. The Independent on Sunday reported allegations that "scores" of the 1.5 million the UK public who use benzodiazepines long-term have symptoms that are consistent with brain damage. It has been described as a 'huge scandal' by Jim Dobbin, and legal experts and MPs have predicted a class action lawsuit. A solicitor said she was aware of the past failed litigation against the drug companies and the relevance the documents had to that court case and said it was strange that the documents were kept 'hidden' by the MRC.
Professor Lader, who chaired the MRC meeting, declined to speculate as to why the MRC declined to support his request to set up a unit to further research benzodiazepines and why they did not set up a special safety committee to look into these concerns. Professor Lader stated that he regrets not being more proactive on pursuing the issue, stating that he did not want to be labeled as the guy who pushed only issues with benzos. Professor Ashton also submitted proposals for grant-funded research using MRI, EEG, and cognitive testing in a ramdomised controlled trial to assess whether benzodiazepines have permanent damage to the brain, but similar to Professor Lader got turned down by the MRC.
The MRC spokesperson said they accept the conclusions of Professor Lader's research and said that they fund only research that meets required quality standards of scientific research, and stated that they were and continue to remain receptive to applications for research in this area. No explanation was reported for why the documents were sealed by the Public Records Act.
Jim Dobbin, who chairs the All-Party Parliamentary Group for Involuntary Tranquilliser Addiction, stated that:
"Many victims have lasting physical, cognitive and psychological problems even after they have withdrawn. We are seeking legal advice because we believe these documents are the bombshell they have been waiting for. The MRC must justify why there was no proper follow-up to Professor Lader's research, no safety committee, no study, nothing to further explore the results. We are talking about a huge scandal here."
The legal director of Action Against Medical Accidents said urgent research must be carried out and said that, if the results of larger studies confirm professor Lader's research, the government and MRC could be faced with one of the biggest group actions for damages the courts have ever seen given the large number of people potentially affected. People who report enduring symptoms post-withdrawal such as neurological pain, headaches, cognitive impairment, and memory loss have been left in the dark as to whether these symptoms are drug-induced damage or not due to the MRC's inaction, it was reported. Professor Lader reported that the results of his research did not surprise his research group given that it was already known that alcohol could cause permanent brain changes.
Benzodiazepines have a unique history in that they were responsible for the largest-ever class-action lawsuit against drug manufacturers in the United Kingdom, in the 1980s and early 1990s, involving 14,000 patients and 1,800 law firms that alleged the manufacturers knew of the dependence potential but intentionally withheld this information from doctors. At the same time, 117 general practitioners and 50 health authorities were sued by patients to recover damages for the harmful effects of dependence and withdrawal. This led some doctors to require a signed consent form from their patients and to recommend that all patients be adequately warned of the risks of dependence and withdrawal before starting treatment with benzodiazepines. The court case against the drug manufacturers never reached a verdict; legal aid had been withdrawn, leading to the collapse of the trial, and there were allegations that the consultant psychiatrists, the expert witnesses, had a conflict of interest. This litigation led to changes in the British law, making class action lawsuits more difficult.
Benzodiazepines have been found to cause teratogenic malformations. The literature concerning the safety of benzodiazepines in pregnancy is unclear and controversial. Initial concerns regarding benzodiazepines in pregnancy began with alarming findings in animals but these do not necessarily cross over to humans. Conflicting findings have been found in babies exposed to benzodiazepines. A recent analysis of the Swedish Medical Birth Register found an association with preterm births, low birth weight and a moderate increased risk for congental malformations. An increase in pylorostenosis or alimentary tract atresia was seen. An increase in orofacial clefts was not demonstrated however and it was concluded that benzodiazepines are not major teratogens.
Neurodevelopmental disorders and clinical symptoms are commonly found in babies exposed to benzodiazepines in utero. Benzodiazepine-exposed babies have a low birth weight but catch up to normal babies at an early age, but smaller head circumferences found in benzo babies persists. Other adverse effects of benzodiazepines taken during pregnancy are deviating neurodevelopmental and clinical symptoms including craniofacial anomalies, delayed development of pincer grasp, deviations in muscle tone and pattern of movements. Motor impairments in the babies are impeded for up to 1 year after birth. Gross motor development impairments take 18 months to return to normal but fine motor function impairments persist. In addition to the smaller head circumference found in benzodiazepine-exposed babies mental retardation, functional deficits, long-lasting behavioural anomalies, and lower intelligence occurs.
Benzodiazepines, like many other sedative hypnotic drugs causes apoptotic neuronal cell death. However, benzodiazepines do not cause as severe apoptosis to the developing brain as alcohol does. The prenatal toxicity of benzodiazepines is most likely due to their effects on neurotransmitter systems, cell membranes and protein synthesis. This however, is complicated in that neuropsychological or neuropsychiatric effects of benzodiazepines, if they occur, may not become apparent until later childhood or even adolescence. A review of the literature found data on long-term follow-up regarding neurobehavioural outcomes is very limited. However, a study was conducted that followed up 550 benzodiazepine-exposed children, which found that, overall, most children developed normally. There was a smaller subset of benzodiazepine-exposed children who were slower to develop, but by four years of age most of this subgroup of children had normalised. There were a small number benzodiazepine-exposed children who had continuing developmental abnormalities at 4-year follow-up, but it was not possible to conclude whether these deficits were the result of benzodiazepines or whether social and environmental factors explained the continuing deficits.
Concerns regarding whether benzodiazepines during pregnancy cause major malformations, in particular cleft palet have been hotly debated in the literature. A meta analysis of the data from cohort studies found no link but meta analysis of case control studies did find a significant increase in major malformations (however, the cohort studies were homogenous and the case control studies were heterogeneous, thus reducing the strength of the case control results). There have also been several reports that suggest that benzodiazepines have the potential to cause a syndrome similar to fetal alcohol syndrome, but this has been disputed by a number of studies. As a result of conflicting findings use of benzodiazepines during pregnancy is controversial. The best available evidence suggests that benzodiazepines are not a major cause of birth defects, i.e. major malformations or cleft lip or cleft palet.
Significant toxicity from benzodiazepines can occur in the elderly as a result of long-term use. Benzodiazepines, along with antihypertensives and drugs affecting the cholinergic system are the most common cause of drug-induced dementia affecting over 10 percent of patients attending memory clinics. Long-term use of benzodiazepines in the elderly can lead to a pharmacological syndrome with symptoms including drowsiness, ataxia, fatigue, confusion, weakness, dizziness, vertigo, syncope, reversible dementia, depression, impairment of intellect, psychomotor and sexual dysfunction, agitation, auditory and visual hallucinations, paranoid ideation, panic, delirium, depersonalisation, sleepwalking, aggressivity, orthostatic hypotension and insomnia. Depletion of certain neurotransmitters and cortisol levels and alterations in immune function and biological markers can also occur. Elderly individuals who have been long-term users of benzodiazepines have been found to have a higher incidence of post-operative confusion. Benzodiazepines have been associated with increased body sway in the elderly, which can potentially lead to fatal accidents including falls. Discontinuation of benzodiazepines leads to improvement in the balance of the body and also leads to improvements in cognitive functions in the elderly benzodiazepine hypnotic users without worsening of insomnia.
A review of the evidence has found that whilst long-term use of benzodiazepines impairs memory, its association with causing dementia is not clear and requires further research. A more recent study found that benzodiazepines are associated with an increased risk of dementia and it is recommended that benzodiazepines are avoided in the elderly.
- Ayers, Susan (23 August 2007). Baum, Andrew; McManus, Chris; Newman, Stanton; Wallston, Kenneth; Weinman, John, eds. Cambridge Handbook of Psychology, Health and Medicine (2nd ed.). Cambridge University Press. p. 677. ISBN 978-0-521-87997-2.
- Ford C, Law F (July 2014). "Guidance for the use and reduction of misuse of benzodiazepines and other hypnotics and anxiolytics in general practice" (PDF). smmgp.org.uk.
- Galanter, Marc (1 July 2008). The American Psychiatric Publishing Textbook of Substance Abuse Treatment (American Psychiatric Press Textbook of Substance Abuse Treatment) (4 ed.). American Psychiatric Publishing, Inc. p. 197. ISBN 978-1-58562-276-4.
- Lindsay, S.J.E.; Powell, Graham E., eds. (28 July 1998). The Handbook of Clinical Adult Psychology (2nd ed.). Routledge. p. 173. ISBN 978-0-415-07215-1.
- Haddad, Peter; Deakin, Bill; Dursun, Serdar, eds. (27 May 2004). "Benzodiazepine dependence". Adverse Syndromes and Psychiatric Drugs: A clinical guide. Oxford University Press. pp. 240–252. ISBN 978-0-19-852748-0.
- Hammersley D, Beeley L (1996). "The effects of medication on counselling". In Palmer S, Dainow S, Milner P. Counselling: The BACP Counselling Reader 1. Sage. pp. 211–4. ISBN 978-0-8039-7477-7.
- Onyett SR (April 1989). "The benzodiazepine withdrawal syndrome and its management". J R Coll Gen Pract 39 (321): 160–3. PMC 1711840. PMID 2576073.
- National Drug Strategy; National Drug Law Enforcement Research Fund (2007). "Benzodiazepine and pharmaceutical opioid misuse and their relationship to crime - An examination of illicit prescription drug markets in Melbourne, Hobart and Darwin" (PDF). Retrieved 27 December 2008.
- Juergens, Sm; Morse, Rm (May 1988). "Alprazolam dependence in seven patients". The American Journal of Psychiatry 145 (5): 625–7. doi:10.1176/ajp.145.5.625. ISSN 0002-953X. PMID 3258735.
- Denis C, Fatséas M, Lavie E, Auriacombe M (July 2006). Denis, Cecile, ed. "Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings" (PDF). Cochrane Database Syst Rev 3: CD005194. doi:10.1002/14651858.CD005194.pub2. PMID 16856084.
- Rickels K, Lucki I, Schweizer E, García-España F, Case WG (April 1999). "Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation". J Clin Psychopharmacol 19 (2): 107–13. doi:10.1097/00004714-199904000-00003. PMID 10211911.
- Belleville G, Morin CM (March 2008). "Hypnotic discontinuation in chronic insomnia: impact of psychological distress, readiness to change, and self-efficacy". Health Psychol 27 (2): 239–48. doi:10.1037/0278-6220.127.116.11. PMID 18377143.
- Charlson, F; Degenhardt, L; McLaren, J; Hall, W; Lynskey, M (February 2009). "A systematic review of research examining benzodiazepine-related mortality". Pharmacoepidemiol Drug Saf 18 (2): 93–103. doi:10.1002/pds.1694. PMID 19125401.
- Uzun, S.; Kozumplik, O.; Jakovljević, M.; Sedić, B. (Mar 2010). "Side effects of treatment with benzodiazepines". Psychiatr Danub 22 (1): 90–3. PMID 20305598.
- Mr. Phil Woolas; Mr. John Hutton (7 Dec 1999). "Benzodiazepines". England: www.parliament.uk.
The story of benzodiazepines is of awesome proportions and has been described as a national scandal. The impact is so large that it is too big for Governments, regulatory authorities, and the pharmaceutical industry to address head on, so the scandal has been swept under the carpet. My reasons for bringing the debate to the Chamber are numerous and reflect the many strands that weave through the issue.
- Semple, David; Roger Smyth; Jonathan Burns; Rajan Darjee; Andrew McIntosh (2007) . "13". Oxford Handbook of Psychiatry. United Kingdom: Oxford University Press. p. 540. ISBN 0-19-852783-7.
- Collier, Judith; Longmore, Murray (2003). "4". In Scally, Peter. Oxford Handbook of Clinical Specialties (6 ed.). Oxford University Press. p. 366. ISBN 978-0-19-852518-9.
- Cohen LS, Rosenbaum JF (October 1987). "Clonazepam: new uses and potential problems". J Clin Psychiatry. 48 Suppl: 50–6. PMID 2889724.
- McLeod DR, Hoehn-Saric R, Labib AS, Greenblatt DJ (April 1988). "Six weeks of diazepam treatment in normal women: effects on psychomotor performance and psychophysiology". J Clin Psychopharmacol 8 (2): 83–99. doi:10.1097/00004714-198804000-00002. PMID 3372718.
- Paltiel O; Marzec-Boguslawska A; Soskolne V; et al. (December 2004). "Use of tranquilizers and sleeping pills among cancer patients is associated with a poorer quality of life" (PDF). Qual Life Res 13 (10): 1699–706. doi:10.1007/s11136-004-8745-1. PMID 15651540.
- Berger, A.; Edelsberg, J.; Treglia, M.; Alvir, JM.; Oster, G. (Oct 2012). "Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: a retrospective cohort study.". BMC Psychiatry 12 (1): 177. doi:10.1186/1471-244X-12-177. PMC 3504522. PMID 23088742.
- Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004). "Cognitive effects of long-term benzodiazepine use: a meta-analysis". CNS Drugs 18 (1): 37–48. doi:10.2165/00023210-200418010-00004. PMID 14731058.
- Golombok S; Moodley P; Lader M (May 1988). "Cognitive impairment in long-term benzodiazepine users". Psychol Med 18 (2): 365–74. doi:10.1017/S0033291700007911. PMID 2899898.
- Stewart SA (2005). "The effects of benzodiazepines on cognition". J Clin Psychiatry. 66 Suppl 2: 9–13. PMID 15762814.
- Barker MJ, Greenwood KM, Jackson M, Crowe SF (April 2004). "Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis". Arch Clin Neuropsychol 19 (3): 437–54. doi:10.1016/S0887-6177(03)00096-9. PMID 15033227.
- Tata PR; Rollings J; Collins M; Pickering A; Jacobson RR (February 1994). "Lack of cognitive recovery following withdrawal from long-term benzodiazepine use". Psychol Med 24 (1): 203–13. doi:10.1017/S0033291700026969. PMID 8208885.
- Paterniti S, Dufouil C, Alpérovitch A (June 2002). "Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study". J Clin Psychopharmacol 22 (3): 285–93. doi:10.1097/00004714-200206000-00009. PMID 12006899.
- Carl Salzman; Janina Fisher; Kenneth Nobel; Randy Glassman; Abbie Wolfson; Margaret Kelley (2004). "Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents" (PDF). International Journal of Geriatric Psychiatry 7 (2): 89–93. doi:10.1002/gps.930070205.
- Kiliç C, Curran HV, Noshirvani H, Marks IM, Başoğlu M (January 1999). "Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia/panic patients". Psychol Med 29 (1): 225–31. doi:10.1017/S003329179800734X. PMID 10077311.
- Ashton, Heather (2005-05-01). "The diagnosis and management of benzodiazepine dependence". Current Opinion in Psychiatry 18 (3): 249–255. doi:10.1097/01.yco.0000165594.60434.84. ISSN 0951-7367. PMID 16639148.
- Morin, Charles M.; Bélanger, Lynda; Bastien, Célyne; Vallières, Annie (2005-01-01). "Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse". Behaviour Research and Therapy 43 (1): 1–14. doi:10.1016/j.brat.2003.12.002. ISSN 0005-7967. PMID 15531349.
- Poyares, Dalva; Guilleminault, Christian; Ohayon, Maurice M.; Tufik, Sergio (2004-06-01). "Chronic benzodiazepine usage and withdrawal in insomnia patients". Journal of Psychiatric Research 38 (3): 327–334. doi:10.1016/j.jpsychires.2003.10.003. ISSN 0022-3956. PMID 15003439.
- Lee-chiong, Teofilo (24 April 2008). Sleep Medicine: Essentials and Review. Oxford University Press, USA. p. 105. ISBN 0-19-530659-7.
- Guina, Jeffrey; Rossetter, Sarah R.; DeRHODES, Bethany J.; Nahhas, Ramzi W.; Welton, Randon S. (2015-07-01). "Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis". Journal of Psychiatric Practice 21 (4): 281–303. doi:10.1097/PRA.0000000000000091. ISSN 1538-1145. PMID 26164054.
- Semple, David; Roger Smyth; Jonathan Burns; Rajan Darjee; Andrew McIntosh (2007) . "13". Oxford Handbook of Psychiatry. United Kingdom: Oxford University Press. p. 540. ISBN 0-19-852783-7.
- American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders, fifth edition. Arlington, VA: American Psychiatric Association.
- Collier, Judith; Longmore, Murray (2003). "4". In Scally, Peter. Oxford Handbook of Clinical Specialties (6 ed.). Oxford University Press. p. 366. ISBN 978-0-19-852518-9.
- Professor Heather Ashton (2002). "Benzodiazepines: How They Work and How to Withdraw".
- Lydiard RB, Laraia MT, Ballenger JC, Howell EF (May 1987). "Emergence of depressive symptoms in patients receiving alprazolam for panic disorder". Am J Psychiatry 144 (5): 664–5. doi:10.1176/ajp.144.5.664. PMID 3578580.
- Nathan, RG; Robinson, D; Cherek, DR; Davison, S; Sebastian, S; Hack, M (1 January 1985). "Long-term benzodiazepine use and depression". Am J Psychiatry (American Journal of Psychiatry) 142 (1): 144–5. PMID 2857068.
- Longo, L. P.; Johnson, B. (2000-04-01). "Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives". American Family Physician 61 (7): 2121–2128. ISSN 0002-838X. PMID 10779253.
- Tasman A, Kay J, Lieberman JA, eds (2008). Psychiatry, third edition. Chichester, England: John Wiley & Sons. pp. 2603–2615.
- Burke KC, Meek WJ, Krych R, Nisbet R, Burke JD (February 1995). "Medical services use by patients before and after detoxification from benzodiazepine dependence". Psychiatr Serv 46 (2): 157–60. doi:10.1176/ps.46.2.157. PMID 7712252.
- primary research citation -->[medical citation needed]Cohen SI (February 1995). "Alcohol and benzodiazepines generate anxiety, panic and phobias". J R Soc Med 88 (2): 73–7. PMC 1295099. PMID 7769598.
- <Please add first missing authors to populate metadata.> (December 2004). "What's wrong with prescribing hypnotics?". Drug Ther Bull 42 (12): 89–93. doi:10.1136/dtb.2004.421289. PMID 15587763.
- Tien AY; Anthony JC (August 1990). "Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences". J Nerv Ment Dis 178 (8): 473–80. doi:10.1097/00005053-199017880-00001. PMID 2380692.
- Lydiard, Rb; Laraia, Mt; Ballenger, Jc; Howell, Ef (May 1987). "Emergence of depressive symptoms in patients receiving alprazolam for panic disorder". The American Journal of Psychiatry 144 (5): 664–5. doi:10.1176/ajp.144.5.664. ISSN 0002-953X. PMID 3578580.
- Nathan RG; Robinson D; Cherek DR; Davison S; Sebastian S; Hack M (1 January 1985). "Long-term benzodiazepine use and depression". Am J Psychiatry (American Journal of Psychiatry) 142 (1): 144–5. PMID 2857068.
- Kripke DF (August 21, 2007). "Greater incidence of depression with hypnotic use than with placebo". BMC Psychiatry 7: 42. doi:10.1186/1471-244X-7-42. PMC 1994947. PMID 17711589.
- Professor C Heather Ashton (1987). "Benzodiazepine Withdrawal: Outcome in 50 Patients". British Journal of Addiction 82: 655–671.
- Michelini S; Cassano GB; Frare F; Perugi G (July 1996). "Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders". Pharmacopsychiatry 29 (4): 127–34. doi:10.1055/s-2007-979558. PMID 8858711.
- Ashton H (1991). "Protracted withdrawal syndromes from benzodiazepines". J Subst Abuse Treat (benzo.org.uk) 8 (1–2): 19–28. doi:10.1016/0740-5472(91)90023-4. PMID 1675688.
- Wakakura M, Tsubouchi T, Inouye J (March 2004). "Etizolam and benzodiazepine induced blepharospasm". J. Neurol. Neurosurg. Psychiatr. 75 (3): 506–a. doi:10.1136/jnnp.2003.019869. PMC 1738986. PMID 14966178.
- Cookson JC (September 1995). "Rebound exacerbation of anxiety during prolonged tranquilizer ingestion". J R Soc Med 88 (9): 544. PMC 1295346. PMID 7562864.
- Lechin, F; van der Dijs, B; Vitelli-Flores, G; Báez, S; Lechin, ME; Lechin, AE; Orozco, B; Rada, I; León, G; Jiménez, V (February 1994). "Peripheral blood immunological parameters in long-term benzodiazepine users". Clin Neuropharmacol 17 (1): 63–72. doi:10.1097/00002826-199402000-00007. PMID 7908607.
- Luebke, RW.; Chen, DH.; Dietert, R.; Yang, Y.; King, M.; Luster, MI.; Immunotoxicology, Workgroup (2006). "The comparative immunotoxicity of five selected compounds following developmental or adult exposure". J Toxicol Environ Health B Crit Rev 9 (1): 1–26. doi:10.1080/15287390500194326. PMID 16393867.
- Neutel CI, Patten SB (November 1997). "Risk of suicide attempts after benzodiazepine and/or antidepressant use". Ann Epidemiol 7 (8): 568–74. doi:10.1016/S1047-2797(97)00126-9. PMID 9408553.
- Taiminen TJ (January 1993). "Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients". Acta Psychiatr Scand 87 (1): 45–7. doi:10.1111/j.1600-0447.1993.tb03328.x. PMID 8093823.
- Brent DA; Emslie GJ; Clarke GN; et al. (April 2009). "Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study". Am J Psychiatry 166 (4): 418–26. doi:10.1176/appi.ajp.2008.08070976. PMC 3593721. PMID 19223438.
- Allgulander C, Borg S, Vikander B (December 1984). "A 4-6-year follow-up of 50 patients with primary dependence on sedative and hypnotic drugs". Am J Psychiatry 141 (12): 1580–2. doi:10.1176/ajp.141.12.1580. PMID 6507663.
- Wines JD, Saitz R, Horton NJ, Lloyd-Travaglini C, Samet JH (December 2004). "Suicidal behavior, drug use and depressive symptoms after detoxification: a 2-year prospective study". Drug Alcohol Depend 76 (Suppl): S21–9. doi:10.1016/j.drugalcdep.2004.08.004. PMID 15555813.
- Allgulander C, Ljungberg L, Fisher LD (May 1987). "Long-term prognosis in addiction on sedative and hypnotic drugs analyzed with the Cox regression model". Acta Psychiatr Scand 75 (5): 521–31. doi:10.1111/j.1600-0447.1987.tb02828.x. PMID 3604738.
- Daniel F. Kripke. "Mortality Associated with Prescription Hypnotics". USA: National Center for Biotechnology Information.
- Kripke, Daniel F (2008). "Evidence That New Hypnotics Cause Cancer" (PDF). Department of Psychiatry, UCSD (University of California).
the likelihood of cancer causation is sufficiently strong now that physicians and patients should be warned that hypnotics possibly place patients at higher risk for cancer.
- Rosenberg L; Palmer JR; Zauber AG; et al. (June 1995). "Relation of benzodiazepine use to the risk of selected cancers: breast, large bowel, malignant melanoma, lung, endometrium, ovary, non-Hodgkin's lymphoma, testis, Hodgkin's disease, thyroid, and liver". Am. J. Epidemiol. 141 (12): 1153–60. PMID 7771453.
- Halapy E, Kreiger N, Cotterchio M, Sloan M (August 2006). "Benzodiazepines and risk for breast cancer". Ann Epidemiol 16 (8): 632–6. doi:10.1016/j.annepidem.2005.11.004. PMID 16406246.
- Harlow BL; Cramer DW (March 1995). "Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combined case-control studies (Massachusetts, United States)". Cancer Causes Control 6 (2): 130–4. doi:10.1007/BF00052773. PMID 7749052.
- Dublin S, Rossing MA, Heckbert SR, Goff BA, Weiss NS (February 2002). "Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications" (PDF). Cancer Causes Control 13 (1): 35–45. doi:10.1023/A:1013969611593. PMID 11899116.
- Borg S; Bergman H; Holm L. (1 February 1980). "Neuropsychological impairment and exclusive abuse of sedatives or hypnotics". The American journal of psychiatry. 137 (2): 215–7. doi:10.1176/ajp.137.2.215. PMID 7352578.
- van Hiele LJ (January 1981). "[Can lorazepam be distinguished from other short-acting benzodiazepines in regard to brain damage and withdrawal symptoms?]". Ned Tijdschr Geneeskd (in Dutch and Flemish) 125 (4): 156. PMID 6111030.
- Lader, Mh; Ron, M; Petursson, H (Feb 1984). "Computed axial brain tomography in long-term benzodiazepine users". Psychological Medicine 14 (1): 203–6. doi:10.1017/S0033291700003214. ISSN 0033-2917. PMID 6143338.
- Lennane, Kj (May 1986). "Treatment of benzodiazepine dependence". The Medical journal of Australia 144 (11): 594–7. ISSN 0025-729X. PMID 2872582.
- Schmauss, C; Krieg, Jc (Nov 1987). "Enlargement of cerebrospinal fluid spaces in long-term benzodiazepine abusers". Psychological Medicine 17 (4): 869–73. doi:10.1017/S0033291700000660. ISSN 0033-2917. PMID 2893406.
- Perera, Km; Powell, T; Jenner, Fa (Aug 1987). "Computerized axial tomographic studies following long-term use of benzodiazepines". Psychological Medicine 17 (3): 775–7. doi:10.1017/S0033291700026003. ISSN 0033-2917. PMID 2888147.
- Borg S; Bergman H; Engelbrektson K; Vikander B. (1989). "Dependence on sedative-hypnotics: neuropsychological impairment, field dependence and clinical course in a 5-year follow-up study". British journal of addiction. 84 (5): 547–53. doi:10.1111/j.1360-0443.1989.tb00612.x. PMID 2743035.
- Moodley, P; Golombok, S; Shine, P; Lader, M (Aug 1993). "Computed axial brain tomograms in long-term benzodiazepine users". Psychiatry Research 48 (2): 135–44. doi:10.1016/0165-1781(93)90037-H. PMID 8105500.
- Busto, Ue; Bremner, Ke; Knight, K; Terbrugge, K; Sellers, Em (Feb 2000). "Long-term benzodiazepine therapy does not result in brain abnormalities". Journal of Clinical Psychopharmacology 20 (1): 2–6. doi:10.1097/00004714-200002000-00002. PMID 10653201.
- Kitabayashi Y; Ueda H; Narumoto J; et al. (2001). "Chronic high-dose nitrazepam dependence 123I-IMP SPECT and EEG studies". Addict Biol 6 (3): 257–261. doi:10.1080/13556210120056507. PMID 11900604.
- Professor C Heather Ashton. "Long-Term Effects of Benzodiazepine Usage: Research Proposals, 1995-96". University of Newcastle - School of Neurosciences: benzo.org.uk. Retrieved 10 December 2008.
- Professor C Heather Ashton (29 August 2002). "NO EVIDENCE THAT BENZODIAZEPINES ARE "LOCKED UP" IN TISSUES FOR YEARS". benzo.org.uk. Retrieved 10 December 2008.
- Lawrence, Janna (27 September 2014). "Benzodiazepine use is associated with Alzheimer's disease, study finds". The Pharmaceutical Journal 293 (7829). Retrieved 2014-10-10.
- Marshall, KP.; Georgievskava, Z.; Georgievsky, I. (Jun 2009). "Social reactions to Valium and Prozac: a cultural lag perspective of drug diffusion and adoption". Res Social Adm Pharm 5 (2): 94–107. doi:10.1016/j.sapharm.2008.06.005. PMID 19524858.
- Fraser AD (October 1998). "Use and abuse of the benzodiazepines". Ther Drug Monit 20 (5): 481–9. doi:10.1097/00007691-199810000-00007. PMID 9780123.
- Edwards RA, Medlicott RW (November 1980). "Advantages and disadvantages of benzodiazepine prescription". N. Z. Med. J. 92 (671): 357–9. PMID 6109269.
- Bain KT (June 2006). "Management of chronic insomnia in elderly persons". Am J Geriatr Pharmacother 4 (2): 168–92. doi:10.1016/j.amjopharm.2006.06.006. PMID 16860264.
- Ashton H (1994). "Guidelines for the rational use of benzodiazepines. When and what to use". Drugs 48 (1): 25–40. doi:10.2165/00003495-199448010-00004. PMID 7525193. Retrieved 18 June 2009.
- National Treatment Agency for Substance Misuse (2007). "Drug misuse and dependence - UK guidelines on clinical management" (PDF). United Kingdom: Department of Health.
- Gitlow, Stuart (1 October 2006). Substance Use Disorders: A Practical Guide (2nd ed.). USA: Lippincott Williams and Wilkins. pp. 101–103. ISBN 978-0-7817-6998-3.
- Authier, N.; Balayssac, D.; Sautereau, M.; Zangarelli, A.; Courty, P.; Somogyi, AA.; Vennat, B.; Llorca, PM.; Eschalier, A. (November 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Ann Pharm Fr 67 (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.
- Professor Lader; Professor Morgan, Professor Shepherd, Dr Paul Williams, Dr Skegg, Professor Parish, Dr Peter Tyrer, Dr Inman, Dr John Marks (Ex-Roche), Peter Harris (Roche), Tom Hurry (Wyeth). "Benzodiazepine Dependence Medical Research Council headquarters, Closed until 2014 - Opened 2005" (PDF). England: The National Archives.
30 October 1980 - 3 April 1981Cite uses deprecated parameter
- DrugScope; Gemma Reay; Dr Brian Iddon MP. "All-Party Parliamentary Drugs Misuse Group - An Inquiry into Physical Dependence and Addiction to Prescription and Over-the-Counter Medication" (PDF). UK: DrugScope.org.uk. Retrieved 21 January 2009.
- Dawn Primarolo; David Mellor (18 July 1989). "Benzodiazepines". United Kingdom: Hansard, UK Parliament.
- Audrey Wise; Alan Milburn (6 May 1998). "Benzodiazepines". United Kingdom: Handsard, UK Parliament.
- Yvette Cooper; Phil Woolas (11 November 1999). "Benzodiazepine". United Kingdom: Handsard, UK Parliament.
- Michael Behan; Jim Dobbin (20 July 2009). "ALL-PARTY PARLIAMENTARY GROUP ON INVOLUNTARY TRANQUILLISER ADDICTION, SUBMISSION TO EQUALITIES AND HUMAN RIGHTS COMMISSION" (PDF). AddictionToday.org.
The discrimination is large scale, long-standing and deliberate. Government Departments are aware that they are discriminating but reject the available solutions. The discrimination has disastrous effects on the lives of those affected.
- Nina Lakhani (7 November 2010). "Drugs linked to brain damage 30 years ago". United Kingdom: The Independent on Sunday.
- King MB (1992). "Is there still a role for benzodiazepines in general practice?". Br J Gen Pract 42 (358): 202–5. PMC 1372025. PMID 1389432.
- Peart R (1999-06-01). "Memorandum by Dr Reg Peart". Minutes of Evidence. Select Committee on Health, House of Commons, UK Parliament. Retrieved 27 May 2009.
- Mazaira S (2005). "[Effects of psychiatric drugs on the fetus and newborn children. Consequences of the treatment of psychiatric disorders during pregnancy and lactation]". Vertex (in Spanish) 16 (59): 35–42. PMID 15785787.
- McGrath C, Buist A, Norman TR (February 1999). "Treatment of anxiety during pregnancy: effects of psychotropic drug treatment on the developing fetus". Drug Saf 20 (2): 171–86. doi:10.2165/00002018-199920020-00006. PMID 10082073.
- Wikner BN, Stiller CO, Bergman U, Asker C, Källén B (November 2007). "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations". Pharmacoepidemiol Drug Saf 16 (11): 1203–10. doi:10.1002/pds.1457. PMID 17894421.
- L, Laegreid; Hagberg G; Lundberg A (April 1992). "Neurodevelopment in late infancy after prenatal exposure to benzodiazepines—a prospective study". Neuropediatrics 23 (2): 60–7. doi:10.1055/s-2008-1071314. PMID 1351263.
- L, Laegreid (1990). "Clinical observations in children after prenatal benzodiazepine exposure". Dev Pharmacol Ther 15 (3–4): 186–8. PMID 1983095.
- Karkos, J (December 1991). "The neurotoxicity of benzodiazepines". Fortschritte der Neurologie · Psychiatrie 59 (12): 498–520. doi:10.1055/s-2007-1000726. PMID 1685467.
- Ikonomidou C; Bittigau P; Koch C; et al. (August 2001). "Neurotransmitters and apoptosis in the developing brain". Biochem. Pharmacol. 62 (4): 401–5. doi:10.1016/S0006-2952(01)00696-7. PMID 11448448.
- Gressens P, Mesples B, Sahir N, Marret S, Sola A (April 2001). "Environmental factors and disturbances of brain development". Semin Neonatol 6 (2): 185–94. doi:10.1053/siny.2001.0048. PMID 11483023.
- Farber NB, Olney JW (December 2003). "Drugs of abuse that cause developing neurons to commit suicide". Brain Res. Dev. Brain Res. 147 (1–2): 37–45. doi:10.1016/j.devbrainres.2003.09.009. PMID 14741749.
- Karkos J (December 1991). "[The neurotoxicity of benzodiazepines]". Fortschr Neurol Psychiatr (in German) 59 (12): 498–520. doi:10.1055/s-2007-1000726. PMID 1685467.
- Kellogg CK (1985). "Drugs and chemicals that act on the central nervous system: interpretation of experimental evidence". Prog. Clin. Biol. Res. 163C: 147–53. PMID 3887421.
- Austin MP, Mitchell PB (October 1998). "Psychotropic medications in pregnant women: treatment dilemmas". Med. J. Aust. 169 (8): 428–31. PMID 9830392.
- McElhatton PR (1994). "The effects of benzodiazepine use during pregnancy and lactation". Reprod. Toxicol. 8 (6): 461–75. doi:10.1016/0890-6238(94)90029-9. PMID 7881198.
- Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR (September 1998). "Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies". BMJ 317 (7162): 839–43. doi:10.1136/bmj.317.7162.839. PMC 31092. PMID 9748174.
- Klein-Schwartz W, Oderda GM (January 1991). "Poisoning in the elderly. Epidemiological, clinical and management considerations". Drugs Aging 1 (1): 67–89. doi:10.2165/00002512-199101010-00008. PMID 1794007.
- Starr JM, Whalley LJ (November 1994). "Drug-induced dementia. Incidence, management and prevention". Drug Saf 11 (5): 310–7. doi:10.2165/00002018-199411050-00003. PMID 7873091.
- Inada K, Ishigooka J (January 2004). "[Dementia induced by antianxiety drugs]". Nippon Rinsho (in Japanese). 62 Suppl: 461–5. PMID 15011406.
- Lechin F, van der Dijs B, Benaim M (1996). "Benzodiazepines: tolerability in elderly patients". Psychother Psychosom 65 (4): 171–82. doi:10.1159/000289072. PMID 8843497.
- Wolkove, N.; Elkholy, O.; Baltzan, M.; Palayew, M. (May 2007). "Sleep and aging: 2. Management of sleep disorders in older people". CMAJ 176 (10): 1449–54. doi:10.1503/cmaj.070335. PMC 1863539. PMID 17485699.
- Tsunoda, K.; Uchida, H.; Suzuki, T.; Watanabe, K.; Yamashima, T.; Kashima, H. (Jan 2010). "Effects of discontinuing benzodiazepine-derivative hypnotics on postural sway and cognitive functions in the elderly". Int J Geriatr Psychiatry 25 (12): 1259–65. doi:10.1002/gps.2465. PMID 20054834.
- Hulse GK, Lautenschlager NT, Tait RJ, Almeida OP (2005). "Dementia associated with alcohol and other drug use". Int Psychogeriatr 17 (Suppl 1): S109–27. doi:10.1017/S1041610205001985. PMID 16240487.
- Wu CS, Wang SC, Chang IS, Lin KM (July 2009). "The Association Between Dementia and Long-Term Use of Benzodiazepine in the Elderly: Nested Case-Control Study Using Claims Data". Am J Geriatr Psychiatry 17 (7): 614–20. doi:10.1097/JGP.0b013e3181a65210. PMID 19546656.